Welcome to our dedicated page for GRI Bio SEC filings (Ticker: GRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GRI Bio, Inc. (NASDAQ: GRI) SEC filings page provides access to the company’s U.S. Securities and Exchange Commission disclosures, along with AI-generated highlights to help interpret complex documents. As a clinical-stage biopharmaceutical company focused on NKT cell modulators for inflammatory, fibrotic and autoimmune diseases, GRI Bio uses its filings to report on clinical progress, financing transactions, governance matters and risk factors relevant to GRI stock.
Among the most informative documents are Form 10-K annual reports and Form 10-Q quarterly reports, which describe the company’s business, pipeline programs such as GRI-0621 for idiopathic pulmonary fibrosis and type 2 dNKT agonists for systemic lupus erythematosus, and its status as a smaller reporting and emerging growth company. These filings also summarize key agreements, intellectual property and the broader risk profile associated with clinical-stage drug development.
GRI Bio’s Form 8-K current reports highlight material events, including:
- Topline and interim data from the Phase 2a GRI-0621-IPF-02 trial in IPF, covering safety, biomarker changes, alveolar basement membrane repair markers and forced vital capacity (FVC) analyses.
- Details of public offerings of common stock, pre-funded warrants and Series F warrants, including purchase agreements, warrant terms and expected use of proceeds.
- Corporate actions such as amendments to the 2018 Equity Incentive Plan and annual meeting voting results.
On this page, users can also review registration statements on Form S-1 and amendments, which outline securities offerings and include extensive exhibit lists covering warrants, purchase agreements and other contracts. Proxy statements (DEF 14A) provide insight into board structure, compensation plans and shareholder proposals.
Stock Titan’s interface surfaces AI-powered summaries of lengthy filings to explain key points in plain language, such as how a financing may affect capital structure or how reported IPF trial data relate to GRI-0621’s development. Real-time updates from EDGAR ensure new 10-K, 10-Q, 8-K, S-1 and related forms appear promptly, while dedicated sections for insider and beneficial ownership information can be explored through the company’s broader filing history.
Use this GRI filings hub to quickly locate and interpret the regulatory documents that shape the investment narrative around GRI Bio’s NKT cell–focused pipeline and its Nasdaq-listed common stock.
GRI Bio, Inc. reported results from its August 13, 2025 virtual Annual Meeting. Stockholders approved an amendment to the Amended and Restated 2018 Equity Incentive Plan, increasing the number of shares reserved for issuance by 400,000 shares. The company noted 2,496,800 shares issued and outstanding as of the July 8, 2025 record date and a quorum of 1,090,373 shares (approximately 43.67%) was present or represented.
At the meeting the board nominees Roelof Rongen and Camilla V. Simpson were elected with 63,031 and 63,581 votes for, respectively, and the appointment of WithumSmith+Brown, PC as independent registered public accounting firm for fiscal 2025 was ratified with 1,072,167 votes for. Exhibit 10.1 contains the amended equity incentive plan text.
GRI Bio (Nasdaq: GRI) furnished an 8-K under Item 7.01 disclosing a press release that reports interim safety results from its Phase 2a study of GRI-0621 for idiopathic pulmonary fibrosis. The disclosure is provided solely for Regulation FD purposes and is expressly not deemed “filed” under the Exchange Act. No efficacy data, financial metrics, or guidance updates were included. Exhibit 99.1 contains the full press release; no other material items were reported.
FAQ
What is the current stock price of GRI Bio (GRI)?
What is the market cap of GRI Bio (GRI)?
